Retinoids ameliorate insulin resistance in a leptin-dependent manner in mice

Hepatology

Volumn 56, Issue 4, 2012, Pages 1319-1330

  Tsuchiya, Hiroyuki ^a   Ikeda, Yoshito ^a   Ebata, Yu ^a   Kojima, Chihiro ^a   Katsuma, Rikutaro ^a   Tsuruyama, Tatsuaki ^b   Sakabe, Tomohiko ^c   Shomori, Kohei ^d   Komeda, Noriko ^a   Oshiro, Shoko ^a   Okamoto, Hideharu ^d   Takubo, Kazuko ^d   Hama, Susumu ^a   Shudo, Koichi ^e   Kogure, Kentaro ^a   Shiota, Goshi ^c  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

^d TOTTORI UNIVERSITY   (Japan)

^e Kawasaki   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN RECEPTOR SUBSTRATE 1; JANUS KINASE 2; LEPTIN; LEPTIN RECEPTOR; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; STAT3 PROTEIN; TAMIBAROTENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FATTY LIVER; HEPATOCYTES; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; LEPTIN; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; RANDOM ALLOCATION; RECEPTORS, LEPTIN; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TRETINOIN; UP-REGULATION;

EID: 84867147609     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25798     Document Type: Article

References (43)

1. Watanabe S, Yaginuma R, Ikejima K, Miyazaki A. Liver diseases and metabolic syndrome. J Gastroenterol 2008; 43: 509-518.
2. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. HEPATOLOGY 2010; 51: 1820-1832.
3. Morris DL, Rui L. Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab 2009; 297: E1247-E1259.
4. Mantzoros CS, Magkos F, Brinkoetter M, Sienkiewicz E, Dardeno TA, Kim SY, et al. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab 2011; 301: E567-E584.
5. Marra F. Leptin and liver tissue repair: do rodent models provide the answers? J Hepatol 2007; 46: 12-18.
6. Thorn SR, Meyer MJ, Van Amburgh ME, Boisclair YR. Effect of estrogen on leptin and expression of leptin receptor transcripts in prepubertal dairy heifers. J Dairy Sci 2007; 90: 3742-3750.
7. Javor ED, Ghany MG, Cochran EK, Oral EA, DePaoli AM, Premkumar A, et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. HEPATOLOGY 2005; 41: 753-760.
8. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002; 346: 570-578.
9. Andreelli F, Foretz M, Knauf C, Cani PD, Perrin C, Iglesias MA, et al. Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 2006; 147: 2432-2441.
10. Brabant G, Müller G, Horn R, Anderwald C, Roden M, Nave H. Hepatic leptin signaling in obesity. FASEB J 2005; 19: 1048-1050.
11. Huang W, Dedousis N, Bhatt BA, O'Doherty RM. Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in diet-induced obesity. J Biol Chem 2004; 279: 21695-21700.
12. Akasaka Y, Tsunoda M, Ogata T, Ide T, Murakami K. Direct evidence for leptin-induced lipid oxidation independent of long-form leptin receptor. Biochim Biophys Acta 2010; 1801: 1115-1122.
13. Inoue H, Ogawa W, Ozaki M, Haga S, Matsumoto M, Furukawa K, et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med 2004; 10: 168-174.
14. Kroy DC, Beraza N, Tschaharganeh DF, Sander LE, Erschfeld S, Giebeler A, et al. Lack of interleukin-6/glycoprotein 130/signal transducers and activators of transcription-3 signaling in hepatocytes predisposes to liver steatosis and injury in mice. HEPATOLOGY 2010; 51: 463-473.
15. Inoue H, Ogawa W, Asakawa A, Okamoto Y, Nishizawa A, Matsumoto M, et al. Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab 2006; 3: 267-275.
16. Koch L, Wunderlich FT, Seibler J, Könner AC, Hampel B, Irlenbusch S, et al. Central insulin action regulates peripheral glucose and fat metabolism in mice. J Clin Invest 2008; 118: 2132-2147.
17. Lefebvre P, Martin PJ, Flajollet S, Dedieu S, Billaut X, Lefebvre B. Transcriptional activities of retinoic acid receptors. Vitam Horm 2005; 70: 199-264.
18. Kagechika H, Kawachi E, Hashimoto Y, Shudo K. New type inducers of differentiation of human HL-60 promyelocytic leukemia cells. Terephthalic anilides. Chem Pharm Bull. 1984; 32: 4209-4212.
19. Takeuchi M, Yano T, Omoto E, Takahashi K, Kibata M, Shudo K, et al. Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80. Leuk Lymphoma 1998; 31: 441-451.
20. Sato M, Shudo K, Hiragun A. Functional studies of newly synthesized benzoic acid derivatives: identification of highly potent retinoid-like activity. J Cell Physiol 1988; 135: 179-188.
21. Berry DC, Noy N. All-trans-retinoic acid represses obesity and insulin resistance by activating both peroxisome proliferation-activated receptor b/d and retinoic acid receptor. Mol Cell Biol 2009; 29: 3286-3296.
22. Ashla AA, Hoshikawa Y, Tsuchiya H, Hashiguchi K, Enjoji M, Nakamuta M, et al. Genetic analysis of expression profile involved in retinoid metabolism in non-alcoholic fatty liver disease. Hepatol Res 2010; 40: 594-604.
23. Tsuchiya H, Akechi Y, Ikeda R, Nishio R, Sakabe T, Terabayashi K, et al. Suppressive effects of retinoids on iron-induced oxidative stress in the liver. Gastroenterology 2009; 136: 341-350.
24. Yanagitani A, Yamada S, Yasui S, Shimomura T, Murai R, Murawaki Y, et al. Retinoic acid receptor alpha dominant negative form causes steatohepatitis and liver tumors in transgenic mice. HEPATOLOGY 2004; 40: 366-375.
25. Helaly GF, Hussein NG, Refai W, Ibrahim M. Relation of serum insulin-like growth factor-1 (IGF-1) levels with hepatitis C virus infection and insulin resistance. Transl Res 2011; 158: 155-162.
26. Yanai N, Suzuki M, Obinata M. Hepatocyte cell lines established from transgenic mice harboring temperature-sensitive simian virus 40 large T-antigen gene. Exp Cell Res 1991; 197: 50-56.
27. Panchal SK, Brown L. Rodent models for metabolic syndrome research. J Biomed Biotechnol. 2011; 2011: 351982.
28. Shimano H. Sterol regulatory element-binding protein family as global regulators of lipid synthetic genes in energy metabolism. Vitam Horm. 2002; 65: 167-194.
29. Hedbacker K, Birsoy K, Wysocki RW, Asilmaz E, Ahima RS, Farooqi IS, et al. Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metab 2010; 11: 11-22.
30. Bjørbaek C, Buchholz RM, Davis SM, Bates SH, Pierroz DD, Gu H, et al. Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem 2001; 276: 4747-4755.
31. Sandelin A, Wasserman WW. Prediction of nuclear hormone receptor response elements. Mol Endocrinol 2005; 19: 595-606.
32. Loudig O, Babichuk C, White J, Abu-Abed S, Mueller C, Petkovich M. Cytochrome P450RAI(CYP26) promoter: a distinct composite retinoic acid response element underlies the complex regulation of retinoic acid metabolism. Mol Endocrinol 2000; 14: 1483-1497.
33. Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab 2009; 9: 35-51.
34. Tups A. Physiological models of leptin resistance. J Neuroendocrinol 2009; 21: 961-971.
35. Bard-Chapeau EA, Li S, Ding J, Zhang SS, Zhu HH, Princen F, et al. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 2011; 19: 629-639.
36. Madiehe AM, Schaffhauser AO, Braymer DH, Bray GA, York DA. Differential expression of leptin receptor in high- and low-fat-fed Osborne-Mendel and S5B/Pl rats. Obes Res 2000; 8: 467-474.
37. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282: 1568-1575.
38. Ruan W, Lai M. Insulin-like growth factor binding protein: a possible marker for the metabolic syndrome? Acta Diabetol 2010; 47: 5-14.
39. Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008; 48: 993-999.
40. Rutledge AC, Adeli K. Fructose and the metabolic syndrome: pathophysiology and molecular mechanisms. Nutr Rev 2007; 65: S13-S23.
41. Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009; 119: 1322-1334.
42. Gorden DL, Ivanova PT, Myers DS, McIntyre JO, Vansaun MN, Wright JK, et al. Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model. PLoS ONE 2011; 6: e22775.
43. Siegenthaler G, Hotz R, Chatellard-Gruaz D, Didierjean L, Hellman U, Saurat JH. Purification and characterization of the human epidermal fatty acid-binding protein: localization during epidermal cell differentiation in vivo and in vitro. Biochem J 1994; 302: 363-371.